PDCD1LG2 and neoplasm: From the above, the tumor‐targeting formulation, ETP‐PtFeNP, could not only induce a significant immunogenic cell death, but also reverse the PD‐L2 mediated immunosuppression in tumor microenvironment, which synergistically elicited an effective antitumor immune response to enhance the inhibition of tumor growth in vivo.